Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Intellia Therapeutics ( (NTLA) ).
On October 27, 2025, Intellia Therapeutics announced a temporary pause in dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nexiguran ziclumeran (nex-z) due to a report of severe liver issues in a patient. This decision affects trials for transthyretin amyloidosis with cardiomyopathy and polyneuropathy, involving over 650 and 47 patients respectively. The company is consulting with experts and regulatory authorities to address the safety concerns and strategize resuming the trials, highlighting its commitment to patient safety and regulatory compliance.
The most recent analyst rating on (NTLA) stock is a Hold with a $29.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.
Spark’s Take on NTLA Stock
According to Spark, TipRanks’ AI Analyst, NTLA is a Neutral.
Intellia Therapeutics’ overall stock score is driven by strong technical indicators and positive earnings call sentiment, reflecting progress in clinical trials and financial stability. However, financial performance remains a concern due to ongoing losses and negative cash flows, typical of a biotech firm in development. Valuation is challenging with a negative P/E ratio, but the company’s strategic focus on growth and innovation offers potential long-term rewards.
To see Spark’s full report on NTLA stock, click here.
More about Intellia Therapeutics
Intellia Therapeutics, Inc. is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company is dedicated to developing novel, first-in-class medicines that address unmet medical needs and advance treatment paradigms for patients. Intellia is expanding its CRISPR-based platform with innovative editing and delivery technologies.
Average Trading Volume: 5,647,273
Technical Sentiment Signal: Hold
Current Market Cap: $2.75B
For detailed information about NTLA stock, go to TipRanks’ Stock Analysis page.